The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Public health actions to control new SARS-CoV-2 variants
Open accessAbstract
Recent reports suggest that some SARS-CoV-2 genetic variants, such as B.1.1.7, might be more transmissible and are quickly spreading around the world. As the emergence of more transmissible variants could exacerbate the pandemic, we provide public health guidance for increased surveillance and measures to reduce community transmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 2×
“In late 2020, genomic surveillance in South Africa revealed a new SARSCoV-2 variant (designated B.1.351 or 501Y.V2) associated with a concerning rise in local COVID-19 cases (Tegally et al., 2020).”
BackgroundInfluentialDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · cited 1×
“…estimated that B.1.1.7 is approximately 50% more transmissible (Davies et al., 2020), which could increase the average number of people that one infected person will pass the virus to (effective reproductive rate) by between 0.4 and 0.7 people (Volz et al., 2021).”
BackgroundInfluentialAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178 · cited 2×
“One of the mutations in this variant, N501Y, is located in the important receptor-binding domain (RBD) of spike protein, and is predicted to increase binding to human cells and reduce viral neutralization by the monoclonal antibody LY-CoV016 (Greaney et al., 2021; Starr et al., 2020).”
BackgroundGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Genetic Variants of SARS-CoV-2—What Do They Mean?
Lauring, A. S., & Hodcroft, E. B. (2021) · JAMA · doi:10.1001/jama.2020.27124 · Cited by 604
Self-citationInternational Health Regulations (2005)
Merianos, A., & Peiris, M. J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67508-3 · Cited by 524
On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community
Goldstein, E., Lipsitch, M., & Çevik, M. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa691 · Cited by 367
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptationPreprint
Kemp, S. A., Collier, D. A., Datir, R. P., et al. (2020) · medRxiv · doi:10.1101/2020.12.05.20241927 · Cited by 180
Grépin, K. A., Ho, T. L., Liu, Z., Marion, S., Piper, J., Worsnop, C. Z., & Lee, K. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004537 · Cited by 163
Travel restrictions hampering COVID-19 response
Devi, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30967-3 · Cited by 159
On the effect of age on the transmission of SARS-CoV-2 in households, schools and the communityPreprint
Goldstein, E., Lipsitch, M., & Çevik, M. (2020) · medRxiv · doi:10.1101/2020.07.19.20157362 · Cited by 91
Policy opportunities to enhance sharing for pandemic research
Rourke, M. F., Eccleston-Turner, M., Phelan, A., & Gostin, L. O. (2020) · Science · doi:10.1126/science.abb9342 · Cited by 40
Self-citationGrépin, K. A., Ho, T. L., Liu, Z., et al. (2020) · medRxiv · doi:10.1101/2020.11.23.20236703 · Cited by 19
Research works printed but not linked: 1
- Davies, 2020, Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England, medRxiv
Cited by
Sorted by citations
SARS-CoV-2 viral load and shedding kinetics
Puhach, O., Meyer, B., & Eckerle, I. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00822-w · Cited by 462
Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., et al. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00055-4 · Cited by 304
Global disparities in SARS-CoV-2 genomic surveillance
Brito, A. F., Semenova, E., Dudas, G., Hassler, G. W., Kalinich, C. C., Kraemer, M. U. G., Ho, J., Tegally, H., Githinji, G., Agoti, C. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33713-y · Cited by 366
SARS-CoV-2 spreads through cell-to-cell transmission
Zeng, C., Evans, J. P., King, T., Zheng, Y.-M., Oltz, E. M., Whelan, S. P. J., Saif, L. J., Peeples, M. E., & Liu, S.-L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111400119 · Cited by 246
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
Munnink, B. B. O., Worp, N., Nieuwenhuijse, D. F., Sikkema, R. S., Haagmans, B. L., Fouchier, R. A. M., & Koopmans, M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01472-w · Cited by 238
Metadata
- Authors
- Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L., & Cevik, M.
- Affiliations
- Yale University (US)
- University of Bern (CH)
- Georgetown University (US)
- Corresponding author
- Hodcroft, Emma B.
- Fauver, Joseph R.
- Phelan, Alexandra L.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 184
- Issue
- 5
- Pages
- 1127-1132
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7846239
- OpenAlex
- W3127798546
- Cited by
- 147
- References
- 20
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 21 · 2022: 48 · 2021: 56
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 368 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- George Mason University
- Centers for Disease Control and Prevention (75D30120C09570)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Social Sciences › Sociology and Political Science › COVID-19 Prevention and Impact
- Keywords
- SARS-CoV-2 variants, B.1.1.7 variant, Omicron variant, transmissibility, variant surveillance, public health measures, COVID-19 pandemic
- MeSH terms
- COVID-19, SARS-CoV-2, Age Factors, Communicable Disease Control, United Kingdom, Humans, Travel, Global Health, Vulnerable Populations, Mandatory Programs, Pandemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
